Completion of therapy by medicare patients with stage III colon cancer

Sharon A. Dobie, Laura Mae Baldwin, Jason A. Dominitz, Barbara Matthews, Kevin Billingsley, William Barlow

    Research output: Contribution to journalArticle

    106 Citations (Scopus)

    Abstract

    Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. Results: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. Conclusions: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.

    Original languageEnglish (US)
    Pages (from-to)610-619
    Number of pages10
    JournalJournal of the National Cancer Institute
    Volume98
    Issue number9
    DOIs
    StatePublished - May 3 2006

    Fingerprint

    Adjuvant Chemotherapy
    Medicare
    Colonic Neoplasms
    SEER Program
    Drug Therapy
    Mortality
    Physicians
    Therapeutics
    Widowhood
    Neoplasms
    Logistic Models
    Demography
    Confidence Intervals
    Psychology

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Completion of therapy by medicare patients with stage III colon cancer. / Dobie, Sharon A.; Baldwin, Laura Mae; Dominitz, Jason A.; Matthews, Barbara; Billingsley, Kevin; Barlow, William.

    In: Journal of the National Cancer Institute, Vol. 98, No. 9, 03.05.2006, p. 610-619.

    Research output: Contribution to journalArticle

    Dobie, Sharon A. ; Baldwin, Laura Mae ; Dominitz, Jason A. ; Matthews, Barbara ; Billingsley, Kevin ; Barlow, William. / Completion of therapy by medicare patients with stage III colon cancer. In: Journal of the National Cancer Institute. 2006 ; Vol. 98, No. 9. pp. 610-619.
    @article{73541a40e7c8446887d22d4d8d3e2cb4,
    title = "Completion of therapy by medicare patients with stage III colon cancer",
    abstract = "Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. Results: Of the 3193 patients, 2497 (78.2{\%}) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95{\%} confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. Conclusions: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.",
    author = "Dobie, {Sharon A.} and Baldwin, {Laura Mae} and Dominitz, {Jason A.} and Barbara Matthews and Kevin Billingsley and William Barlow",
    year = "2006",
    month = "5",
    day = "3",
    doi = "10.1093/jnci/djj159",
    language = "English (US)",
    volume = "98",
    pages = "610--619",
    journal = "Journal of the National Cancer Institute",
    issn = "0027-8874",
    publisher = "Oxford University Press",
    number = "9",

    }

    TY - JOUR

    T1 - Completion of therapy by medicare patients with stage III colon cancer

    AU - Dobie, Sharon A.

    AU - Baldwin, Laura Mae

    AU - Dominitz, Jason A.

    AU - Matthews, Barbara

    AU - Billingsley, Kevin

    AU - Barlow, William

    PY - 2006/5/3

    Y1 - 2006/5/3

    N2 - Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. Results: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. Conclusions: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.

    AB - Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer resection. We defined a measure of adjuvant chemotherapy completion as one chemotherapy administration claim in a month. We tested the validity of the created measure and its relation to 3-year cancer mortality adjusted for demographic, clinical, and environmental variables. We explored the association of patient characteristics and treating physician characteristics with chemotherapy completion by use of multivariable logistic regression modeling. Results: Of the 3193 patients, 2497 (78.2%) completed the course. Risk of cancer-related mortality was statistically significantly lower among those completing chemotherapy (relative risk = 0.79, 95% confidence interval = 0.69 to 0.89) than those with no adjuvant therapy. Patients who were female, widowed, increasingly elderly, rehospitalized, and living in certain regions were less likely to complete adjuvant chemotherapy than other patients. Race and other clinical, environmental, and physician characteristics were not associated with completion of therapy. Conclusions: Factors associated with incomplete adjuvant chemotherapy may represent physical frailty, treatment complications, and lack of social and psychological support. Interventions to mitigate these influences are a logical next step toward increasing chemotherapy completion rates.

    UR - http://www.scopus.com/inward/record.url?scp=33646443078&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33646443078&partnerID=8YFLogxK

    U2 - 10.1093/jnci/djj159

    DO - 10.1093/jnci/djj159

    M3 - Article

    C2 - 16670386

    AN - SCOPUS:33646443078

    VL - 98

    SP - 610

    EP - 619

    JO - Journal of the National Cancer Institute

    JF - Journal of the National Cancer Institute

    SN - 0027-8874

    IS - 9

    ER -